Evidence map›Paper›PMID 36980772›Full record

ArticleCancers2023

Frequency of Peripheral CD8+ T Cells Expressing Chemo-Attractant Receptors CCR1, 4 and 5 Increases in NPC Patients with EBV Clearance upon Radiotherapy.

Shweta Mahajan, Hayri E Balcioglu, Astrid Oostvogels, Willem A Dik, K C Allen Chan, Kwok-Wai Lo, Edwin P Hui, Anna Tsang, Joanna Tong, Wai Kei Jacky Lam and 4 more

Open access · goldFull text read
In one paragraph

Article in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 2 citations in OpenAlex.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 2 countries.

Shweta MahajanLaboratory of Tumor Immunology, Department of Medical Oncology, Erasmus MC Cancer Institute, 3015 GD Rotterdam, The Netherlands.ORCID 0000-0002-2671-8382
Hayri E BalciogluLaboratory of Tumor Immunology, Department of Medical Oncology, Erasmus MC Cancer Institute, 3015 GD Rotterdam, The Netherlands.ORCID 0000-0002-0225-0180
Astrid OostvogelsLaboratory of Tumor Immunology, Department of Medical Oncology, Erasmus MC Cancer Institute, 3015 GD Rotterdam, The Netherlands.
Willem A DikLaboratory of Medical Immunology, Department of Immunology, Erasmus MC, 3015 GD Rotterdam, The Netherlands.
K C Allen ChanDepartment of Chemical Pathology, The Chinese University of Hong Kong, Hong Kong SAR, China.
Kwok-Wai LoDepartment of Anatomical and Cellular Pathology, The Chinese University of Hong Kong, Hong Kong SAR, China.ORCID 0000-0002-3488-6124
Edwin P HuiState Key Laboratory of Translational Oncology, Sir YK Pao Centre for Cancer, Department of Clinical Oncology, Hong Kong Cancer Institute, The Chinese University of Hong Kong, Hong Kong SAR, China.ORCID 0000-0002-8134-7019
Anna TsangDepartment of Anatomical and Cellular Pathology, The Chinese University of Hong Kong, Hong Kong SAR, China.
Joanna TongDepartment of Anatomical and Cellular Pathology, The Chinese University of Hong Kong, Hong Kong SAR, China.
Wai Kei Jacky LamDepartment of Chemical Pathology, The Chinese University of Hong Kong, Hong Kong SAR, China.ORCID 0000-0001-8922-5609
Kenneth WongState Key Laboratory of Translational Oncology, Sir YK Pao Centre for Cancer, Department of Clinical Oncology, Hong Kong Cancer Institute, The Chinese University of Hong Kong, Hong Kong SAR, China.ORCID 0000-0003-4995-0819
Anthony T C ChanState Key Laboratory of Translational Oncology, Sir YK Pao Centre for Cancer, Department of Clinical Oncology, Hong Kong Cancer Institute, The Chinese University of Hong Kong, Hong Kong SAR, China.
Brigette B Y MaState Key Laboratory of Translational Oncology, Sir YK Pao Centre for Cancer, Department of Clinical Oncology, Hong Kong Cancer Institute, The Chinese University of Hong Kong, Hong Kong SAR, China.
Reno DebetsLaboratory of Tumor Immunology, Department of Medical Oncology, Erasmus MC Cancer Institute, 3015 GD Rotterdam, The Netherlands.ORCID 0000-0002-3649-807X
Chinese University of Hong Kong · HKErasmus MC Cancer Institute · NLErasmus MC · NL

Funding

Erasmus MC-CUHK grant to advocate inter-institutional collaborations nathe Charlie Lee Precision Immuno-oncology Program of the Chinese University of Hong Kong, Hong Kong SAR nathe Kingboard Charity Foundation na
6 · The paper itself

Abstract

Radiotherapy (RT) is the standard-of-care for Epstein-Barr virus (EBV)-associated nasopharyngeal carcinoma (NPC), where the post-RT clearance of plasma EBV DNA is prognostic. Currently, it is not known whether the post-RT clearance of plasma EBV DNA is related to the presence of circulating T-cell subsets. Blood samples from NPC patients were used to assess the frequency of T-cell subsets relating to differentiation, co-signaling and chemotaxis. Patients with undetectable versus detectable plasma EBV DNA levels post-RT were categorized as clearers vs. non-clearers. Clearers had a lower frequency of PD1+CD8+ T cells as well as CXCR3+CD8+ T cells during RT compared to non-clearers. Clearers exclusively showed a temporal increase in chemo-attractant receptors CCR1, 4 and/or 5, expressing CD8+ T cells upon RT. The increase in CCR-expressing CD8+ T cells was accompanied by a drop in naïve CD8+ T cells and an increase in OX40+CD8+ T cells. Upon stratifying these patients based on clinical outcome, the dynamics of CCR-expressing CD8+ T cells were in concordance with the non-recurrence of NPC. In a second cohort, non-recurrence associated with higher quantities of circulating CCL14 and CCL15. Collectively, our findings relate plasma EBV DNA clearance post-RT to T-cell chemotaxis, which requires validation in larger cohorts.

Indexed as

bloodchemoattractant receptorsEpstein–Barr virusnasopharyngeal carcinomaT-cell subsets

Identifiers

PMID36980772
PMCPMC10047204
OpenAlexW4353072305

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read17
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.